3 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
Follow tapotoclax: new trials by email Literature Review of tapotoclax trials Research Report on tapotoclax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia AMG 176, Azacitidine - Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 1 | Terminated | Amgen | 7 | 2022-11-14 | 2025-07-14 |
| A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies Venetoclax, AMG 176 - Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Terminated | AbbVie | 9 | 2019-03-18 | 2021-12-07 |
| AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia AMG 176, Azacitidine, Itraconazole - Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Terminated | Amgen | 141 | 2016-06-13 | 2025-07-09 |
Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Recurrence (1)
United States (3) · Australia (2) · Germany (2) · Canada (1) · Japan (1)
2015 (1), 2018 (1)